# Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV

> **NCT00516685** · PHASE2,PHASE3 · TERMINATED · sponsor: **Bioven Sdn. Bhd.** · enrollment: 230 (estimated)

## Conditions studied

- Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV

## Interventions

- **BIOLOGICAL:** Recombinant Human rEGF-P64K/Montanide Vaccine

## Key facts

- **NCT ID:** NCT00516685
- **Lead sponsor:** Bioven Sdn. Bhd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 230 (ESTIMATED)
- **Why stopped:** Due to inability of patient enrollment, decision taken to terminate in the interests of patients and later Malaysia is incorporated into global Phase 3 trial.
- **Last updated:** 2011-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516685, "Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00516685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*